Quarterly report · Q2
8086.TEDINET S100PL3A
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥260.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥494.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥242.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥6.4bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥12.9bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥11.6bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥27.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥12.4bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥13.1bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥12.1bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥6.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥7.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥8.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥1.01T | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥930.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥888.3bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥768.6bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥730.5bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥237.2bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥199.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥190.8bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥95.5bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥95.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥89.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥75.0bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥85.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥68.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥25.5bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥41.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥78.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥47.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥23.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥10.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥7.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥38.34 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.99 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.5 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.78 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.54 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥33.97 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥77.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥44.65 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 22.0% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥2.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥340m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥168m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥18.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥18.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥15.3bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥203.9bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥200.8bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥18.6bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥44.9bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥34.1bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10.8bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥849m |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥28.0bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥25.0bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.1bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥276.8bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥260.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥16.8bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥21.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥278.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥260.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥18.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥21.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥295m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥988m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥205m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥17.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥17.6bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥11.7bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥186.8bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥183.4bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥19.6bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥45.2bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥35.0bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥10.2bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥26.5bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥23.4bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥258.4bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥241.8bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥16.6bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥24.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥259.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥242.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥17.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥24.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 643
| Item | Context | Value | Unit |
|---|---|---|---|
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)京都府京都市東山区 | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)ＪＰ ＭＯＲＧＡＮ ＣＨＡＳＥ ＢＡＮＫ ３８５７８１（常任代理人 株式会社みずほ銀行決済営業部） | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)ＳＳＢＴＣ ＣＬＩＥＮＴ ＯＭＮＩＢＵＳ ＡＣＣＯＵＮＴ （常任代理人 香港上海銀行東京支店カストディ業務部） | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)ＯＮＥ ＬＩＮＣＯＬＮ ＳＴＲＥＥＴ， ＢＯＳＴＯＮ ＭＡ ＵＳＡ ０２１１１（東京都中央区日本橋３丁目11番１号） | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)ニプロ株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)大阪市北区本庄西３丁目９番３号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding trade notes receivable discounted or transferred by endorsement (text) | CurrentQuarterInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |